CN108553467A - 改善膈肌功能的方法 - Google Patents

改善膈肌功能的方法 Download PDF

Info

Publication number
CN108553467A
CN108553467A CN201810509450.1A CN201810509450A CN108553467A CN 108553467 A CN108553467 A CN 108553467A CN 201810509450 A CN201810509450 A CN 201810509450A CN 108553467 A CN108553467 A CN 108553467A
Authority
CN
China
Prior art keywords
alkyl
imidazo
pyrazin
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810509450.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·贾斯伯
F·马利克
D·T·威
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of CN108553467A publication Critical patent/CN108553467A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201810509450.1A 2012-04-02 2013-04-01 改善膈肌功能的方法 Pending CN108553467A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261619261P 2012-04-02 2012-04-02
US61/619,261 2012-04-02
CN201380018757.7A CN104379597A (zh) 2012-04-02 2013-04-01 改善膈肌功能的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380018757.7A Division CN104379597A (zh) 2012-04-02 2013-04-01 改善膈肌功能的方法

Publications (1)

Publication Number Publication Date
CN108553467A true CN108553467A (zh) 2018-09-21

Family

ID=49300969

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810509450.1A Pending CN108553467A (zh) 2012-04-02 2013-04-01 改善膈肌功能的方法
CN201380018757.7A Pending CN104379597A (zh) 2012-04-02 2013-04-01 改善膈肌功能的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380018757.7A Pending CN104379597A (zh) 2012-04-02 2013-04-01 改善膈肌功能的方法

Country Status (15)

Country Link
US (2) US20150065525A1 (cg-RX-API-DMAC7.html)
EP (1) EP2834269A4 (cg-RX-API-DMAC7.html)
JP (3) JP6345645B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160046693A (cg-RX-API-DMAC7.html)
CN (2) CN108553467A (cg-RX-API-DMAC7.html)
AU (2) AU2013243671B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014024552A2 (cg-RX-API-DMAC7.html)
CA (1) CA2868507A1 (cg-RX-API-DMAC7.html)
EA (1) EA031183B1 (cg-RX-API-DMAC7.html)
HK (1) HK1206364A1 (cg-RX-API-DMAC7.html)
IL (2) IL234885A0 (cg-RX-API-DMAC7.html)
MX (1) MX354965B (cg-RX-API-DMAC7.html)
PH (1) PH12014502217A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201406270YA (cg-RX-API-DMAC7.html)
WO (1) WO2013151938A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US10272082B2 (en) 2011-07-13 2019-04-30 Cytokinetics, Inc. Combination ALS therapy
SG10201704166RA (en) * 2012-04-11 2017-06-29 Cytokinetics Inc Improving resistance to skeletal muscle fatigue
EP4534538A3 (en) 2012-12-07 2025-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
AU2014229313B2 (en) 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CA2932757C (en) 2013-12-06 2023-10-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
RS63018B1 (sr) 2014-04-29 2022-04-29 Cytokinetics Inc Metode za smanjenje opadanja vitalnog kapaciteta
RU2719583C2 (ru) 2014-06-05 2020-04-21 Вертекс Фармасьютикалз Инкорпорейтед Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
US9987279B2 (en) * 2014-09-09 2018-06-05 Astellas Pharma Inc. Pharmaceutical composition for prevention and/or treatment of urinary incontinence
JP2018516254A (ja) 2015-05-29 2018-06-21 ファイザー・インク バニン１酵素の阻害薬としての新規なヘテロ環化合物
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
CN113666938A (zh) 2016-02-12 2021-11-19 细胞动力学股份有限公司 四氢异喹啉衍生物
EP3484876A1 (en) 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
WO2020254343A1 (en) * 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Digital biomarker
CN114007495A (zh) 2019-06-19 2022-02-01 豪夫迈·罗氏有限公司 数字生物标志物
BR112022000325A2 (pt) 2019-07-11 2022-03-15 Escape Bio Inc Indazois e azaindazois como inibidores de lrrk2
US11981644B2 (en) 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US20240382564A1 (en) * 2023-04-17 2024-11-21 Allysta Pharmaceuticals, Inc. Methods and Compositions for Treating Muscular Dystrophy and Memory Impairment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016669A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
WO2011133888A1 (en) * 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) * 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
AU2001268149B2 (en) * 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
CN1283793C (zh) * 2002-06-03 2006-11-08 北京大学 具有骨骼肌刺激活性和免疫调节作用的趋化素样因子超家族
EP1651638A1 (en) * 2003-08-08 2006-05-03 Janssen Pharmaceutica N.V. Pyridyl piperazinyl ureas
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
WO2009023193A1 (en) * 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
NL2001694C2 (en) * 2008-06-18 2009-12-22 Nasophlex B V Ear stimulator for producing a stimulation signal to an ear.
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016669A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
WO2011133888A1 (en) * 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
徐旋里等: "低氧与膈肌疲劳", 《国际病理科学与临床杂志》 *

Also Published As

Publication number Publication date
MX354965B (es) 2018-03-27
HK1206364A1 (en) 2016-01-08
BR112014024552A2 (pt) 2017-09-19
AU2013243671B2 (en) 2017-09-21
JP2015516957A (ja) 2015-06-18
US20170266192A1 (en) 2017-09-21
AU2013243671A1 (en) 2014-10-16
JP2018131460A (ja) 2018-08-23
JP6345645B2 (ja) 2018-06-20
IL267876B (en) 2021-03-25
MX2014011881A (es) 2016-07-20
SG11201406270YA (en) 2014-10-30
US20150065525A1 (en) 2015-03-05
AU2017272286A1 (en) 2018-01-04
EP2834269A1 (en) 2015-02-11
PH12014502217A1 (en) 2015-01-12
JP2020147607A (ja) 2020-09-17
SG10201701101YA (en) 2017-04-27
EP2834269A4 (en) 2015-12-30
EA031183B1 (ru) 2018-11-30
KR20160046693A (ko) 2016-04-29
CN104379597A (zh) 2015-02-25
AU2017272286B2 (en) 2019-05-09
EA201491605A1 (ru) 2015-03-31
WO2013151938A1 (en) 2013-10-10
IL267876A (en) 2019-09-26
IL234885A0 (en) 2014-12-31
CA2868507A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
CN108553467A (zh) 改善膈肌功能的方法
ES2627347T3 (es) Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina
CN102762570B (zh) 作为jak抑制剂的吡唑衍生物
EP2935260A1 (de) Bet-proteininhibitorische dihydropyridopyrazinone
EA036013B1 (ru) Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53
JP2019523233A (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
BR112020005934A2 (pt) inibidor de pde9 e uso do mesmo
JP2011510010A (ja) ３Ｈ−［１，２，３］トリアゾロ［４，５−ｄ］ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成
AU2018346712A1 (en) P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN104395458A (zh) 改善对骨骼肌疲劳的抵抗力
BR112014023460B1 (pt) Composto, formulação farmacêutica, uso de um composto
BR112015008508A2 (pt) bloqueadores de canal de sódio, método de preparação dos mesmos e uso dos mesmos
PT2809669T (pt) Pirroldicarboxamidas fundidas e seu uso como farmacêuticos
WO2017206962A1 (zh) Flt3激酶的新型抑制剂及其用途
JP7763538B2 (ja) Ｐａｒｐ７阻害剤及びその使用
EP3672957A1 (en) Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors
JP7787893B2 (ja) Ｎａｍｐｔモジュレーターとして有用なピラゾール誘導体
KR102778078B1 (ko) 피라졸 유도체 및 이의 용도
HK1261324A1 (en) Methods for improving diaphragm function
JP2025517635A (ja) 二環式ピペラジノン及びその治療的使用
HK40083035B (zh) Parp7抑制剂及其用途
CN121002030A (zh) 作为毒蕈碱型乙酰胆碱受体m4的正向别构调节剂的噻唑并吡啶衍生物
WO2024131265A1 (zh) 用于治疗PI3Kγ介导的疾病的化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261324

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20180921

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1261324

Country of ref document: HK